Blog Archives

FDA safety communication concerning E-cigarettes

September 05, 2019 – An E-cigarette is a handheld battery-powered vaporizer that simulates smoking by providing some of the behavioral aspects of smoking, including the hand-to-mouth action of smoking, but without burning tobacco. Using an E-cigarette is known as “vaping” and the user is referred to as a “vaper.”

Read more ›

Tags: , , , , , , , , , , ,

Lemtrada: Deleterious unwanted effects in some multiple sclerosis patients

19 April 2019 – Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt, MabCampath and Campt-1H is on the markets for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL),

Read more ›

Tags: , , , , , , , ,

Genomics lab illegally markets genetic tests that claim to predict patient responses to drugs

April 07, 2019 – Consumers are increasingly embracing genetic testing to better understand their individual risk for developing diseases. With this rise in popularity and availability, we’re also seeing significant activity in the field of pharmacogenetics, which is the process of understanding what, if any, role genetics plays in a patient’s reaction to particular drugs,

Read more ›

Tags: , , , , , , , ,

Hydrochlorothiazide and non-melanoma skin cancer: How come?

February 02, 2019 –  This is potential alarming news for millions of patients worldwide suffering from high blood pressure: Health Canada has just completed a safety review of hydrochlorothiazide and has found that prolonged use of the drug could increase a person’s risk for non-melanoma skin cancer.

Read more ›

Tags: , , , , , ,

Febuxostat (Uloric) and its problem with cardiovascular mortality

January 16, 2109 – Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and disputed over time, however, for obvious reasons.

Read more ›

Tags: , , , , , , , ,

Is there breast implant-associated cancer (BIA-ALCL)?

January 09, 2019 – Women should be alerted: Is there a thing like breast implant associated cancer (BIA-ALCL)? Yes, there is. Not every woman with a breast implant will get it, however. In fact, BIA-ALCL seems to be a rather rare condition; unfortunately,

Read more ›

Tags: , , , ,

First ever treatment for Lambert-Eaton myasthenic syndrome (LEMS) FDA approved

December 04, 2018 –  The American Food and Drug Administration (FDA) has just approved its first ever treatment, Amifampridine (Firdapse), for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder for adult patients. LEMS affects the connection between nerves and muscles and causes weakness and other symptoms in affected patients. 

Read more ›

Tags: , , , , , ,

Neural tube defects with Dolutegravir-based HIV medications

May 22, 2018 –The American Food and Drug Administration (FDA) just released a Safety Alert concerning serious neural tube defects that might arise in babies born to women who took HIV medications that contained the active ingredient Dolutegravir. Neural tube defects are birth defects that can occur early in pregnancy when the spinal cord,

Read more ›

Tags: , , , , , , ,

Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer

 

May 05, 2018 – The American Food and Drug Administration (FDA) just approved the combination of Dabrafenib (Tafinlar)/Trametinib (Mekinist) to be administered together for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic),

Read more ›

Tags: , , , , , , , , ,

eHealth: Viz.AI Contact App to alert for stroke in patients

February 15, 2018 – The American Food and Drug Administration (FDA) just permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients.

Read more ›

Tags: , , , , , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Researchers retract paper that suggested Chinese CRISPR twins might die early October 15, 2019
    A pair of researchers from the University of California has retracted a paper they had published in the journal Nature Medicine in which they claimed to have found evidence that the Chinese CRISPR twins might die early. In their retraction, Xinzhu Wei and Rasmus Nielsen report that the reason for the retraction was genotyping bias […]
  • In-office gene therapy for wet age-related macular degeneration is coming October 11, 2019
    Gene therapy is showing promise for one of the most common causes of blindness. Data presented today shows that six patients with wet age-related macular degeneration (AMD) have, so far, gone at least six months without the need for continued injections to control a disease that typically requires treatment every four to six weeks. Researchers […]
  • Powerful new genomics method can be used to reveal the causes of rare genetic diseases October 11, 2019
    A team led by a scientist at Scripps Research has invented a new genomics technique for tracking down the causes of rare genetic diseases.
  • Jumping genes can cause rare developmental disorders in children October 11, 2019
    The largest study of its kind into childhood developmental disorders has discovered that jumping genes cause genetic changes in some patients with undiagnosed neurodevelopmental diseases. The research from the Wellcome Sanger Institute and its collaborators in the NHS Regional Genetics services enabled genetic diagnoses for three children with previously undiagnosed rare developmental diseases who were […]
  • New customized drug treatment bypasses a single child's unique mutation within a year of diagnosis October 10, 2019
    An unprecedented case at Boston Children's Hospital shows that it's possible to do something that's never been done before: identify a patient's unique mutation, design a customized drug to bypass it, manufacture and test the drug, and obtain permission from the Food and Drug Administration (FDA) to begin treating the patient—all in less than one […]
Top